Parasitic infections in travelers and immigrants: Part i protozoa

Future Microbiology

Volumn 10, Issue 1, 2015, Pages 69-86

  Norman, Francesca F ^a   Monge Maillo, Begoña ^a   Martínez Pérez, Ángela ^a   Perez Molina, Jose A ^a   López Vélez, Rogelio ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

African trypanosomiasis; Chagas disease; immigration; leishmaniasis; malaria; neglected diseases; parasitic diseases; travel

Indexed keywords

ALBENDAZOLE; ANTIAMEBIC AGENT; ANTILEISHMANIAL AGENT; ANTIMALARIAL AGENT; ANTITRYPANOSOMAL AGENT;

AFRICAN TRYPANOSOMIASIS; AMEBIASIS; BLOOD TRANSFUSION; CHAGAS DISEASE; CLIMATE CHANGE; CRYPTOSPORIDIOSIS; CYCLOSPORA CAYETANENSIS; CYCLOSPORIASIS; DIAGNOSTIC PROCEDURE; DIARRHEA; DISEASE TRANSMISSION; EMPORIATRICS; ENCEPHALITOZOON; ENTAMOEBA HISTOLYTICA; ENTEROCYTOZOON; GIARDIA INTESTINALIS; GIARDIASIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMIGRANT; IMMUNOCOMPROMISED PATIENT; LEISHMANIASIS; MALARIA; MICROSPORIDIA; MICROSPORIDIOSIS; NONHUMAN; NOSEMA; ORGAN DONOR; PLASMODIUM FALCIPARUM; PLASMODIUM KNOWLESI; PLASMODIUM MALARIAE; PLASMODIUM OVALE; PLASMODIUM VIVAX; PLEISTOPHORA; PRIORITY JOURNAL; PROTOZOAL INFECTION; PROTOZOON; PUBLIC HEALTH; REVIEW; SARCOCYSTOSIS; SPECIES IDENTIFICATION; TOXOPLASMA GONDII; TOXOPLASMOSIS; VITTAFORMA; ETHNOLOGY; MIGRANT; PROTOZOAN INFECTIONS; TRANSMISSION; TRAVEL;

ARTHROPODA; PROTOZOA;

CLIMATE CHANGE; EMIGRANTS AND IMMIGRANTS; HUMANS; PROTOZOAN INFECTIONS; PUBLIC HEALTH; TRAVEL;

EID: 84921490313     PISSN: 17460913     EISSN: 17460921     Source Type: Journal    
DOI: 10.2217/fmb.14.105     Document Type: Review

References (120)

1. UNTWO. Tourism highlights 2012 edition. World Tourism Organization 2013. http://dtxtq4w60xqpw.cloudfront.net/sites
2. World Migration Report 2013. http://publications.iom.int/bookstore/free
3. Utzinger J, Becker SL, Knopp S et al. Neglected tropical diseases: diagnosis, clinical management, treatment and control. Swiss Med. Wkly 142, w13727 (2012).
4. Monge-Maillo B, Jimenez BC, Perez-Molina JA et al. Imported infectious diseases in mobile populations, Spain. Emerg. Infect. Dis. 15, 1745-1752 (2009).
5. Norman FF, Perez de Ayala A, Perez-Molina JA, Monge-Maillo B, Zamarron P, Lopez-Velez R. Neglected tropical diseases outside the tropics. PLoS Negl. Trop. Dis. 4, e762 (2010).
6. Zamarron Fuertes P, Perez-Ayala A, Perez Molina JA et al. Clinical and epidemiological characteristics of imported infectious diseases in Spanish travelers. J. Travel Med. 17, 303-309 (2010).
7. Harvey K, Esposito DH, Han P et al. Centers for Disease Control and Prevention (CDC): surveillance for travel-related disease-GeoSentinel Surveillance System, United States, 1997-2011. MMWR Surveill. Summ. 62, 1-23 (2013).
8. Monge-Maillo B, Norman FF, Perez-Molina JA, Navarro M, Diaz-Menendez M, Lopez-Velez R. Travelers visiting friends and relatives (VFR) and imported infectious disease: travelers, immigrants or both? A comparative analysis. Travel Med. Infect. Dis. 12, 88-94 (2014).
9. Leder K, Tong S, Weld L et al. GeoSentinel Surveillance Network: illness in travelers visiting friends and relatives: a review of the GeoSentinel Surveillance Network. Clin. Infect. Dis. 43, 1185-1193 (2006).
10. Norman FF, Monge-Maillo B, Martínez-Pérez A, Perez-Molina JA, López-Vélez R. Parasitic infections in travelers and immigrants: part II helminths and ectoparasites. Future Microbiol. 10(1), 87-99 (2014).
11. WHO World Malaria Report 2013. www.who.int/malaria/publications
12. Sabatinelli G, Ejov M, Joergensen P. Malaria in the WHO European Region (1971-1999). Euro Surveill. 6, 61-65 (2001)
13. World Health Organization Regional Office for Europe. Centralized information system for infectious dieases (CISID). http://data.euro.who.int/cisid
14. Gautret P, Cramer JP, Field V et al. EuroTravNet Network: infectious diseases among travellers and migrants in Europe, EuroTravNet 2010. Euro Surveill. 17, 20205 (2012).
15. Cullen KA, Arguin PM. Division of Parasitic Diseases and Malaria, Center for Global Health, CDC: Malaria surveillance: United States, 2011. MMWR Surveill. Summ. 62, 1-17 (2013).
16. Kantele A, Marti H, Felger I, Muller D, Jokiranta TS. Monkey malaria in a European traveler returning from Malaysia. Emerg. Infect. Dis. 14, 1434-1436 (2008).
17. Orth H, Jensen BO, Holtfreter MC et al. Plasmodium knowlesi infection imported to Germany, January 2013. Euro Surveill. 18, 20603 (2013).
18. Daneshvar C, Davis TM, Cox-Singh J et al. Clinical and laboratory features of human Plasmodium knowlesi infection. Clin. Infect. Dis. 49, 852-860 (2009).
19. Nolder D, Oguike MC, Maxwell-Scott H et al. An observational study of malaria in British travellers: Plasmodium ovale wallikeri and Plasmodium ovale curtisi differ significantly in the duration of latency. BMJ Open 3, e002711 (2013).
20. Rojo-Marcos G, Rubio-Munoz JM, Ramirez-Olivencia G et al. Comparison of imported Plasmodium ovale curtisi and P. ovale wallikeri infections among patients in Spain, 2005-2011. Emerg. Infect. Dis. 20, 409-416 (2014).
21. Leder K, Torresi J, Brownstein JS et al. GeoSentinel Surveillance Network: travel-associated illness trends and clusters, 2000-2010. Emerg. Infect. Dis. 19, 1049-1073 (2013).
22. Mascarello M, Gobbi F, Angheben A et al. Imported malaria in immigrants to Italy: a changing pattern observed in north eastern Italy. J. Travel Med. 16, 317-321 (2009).
23. Bacaner N, Stauffer B, Boulware DR, Walker PF, Keystone J S. Travel medicine considerations for North American immigrants visiting friends and relatives. JAMA 291, 2856-2864 (2004).
24. Monge-Maillo B, Norman F, Perez-Molina JA, Diaz-Menendez M, Rubio JM, Lopez-Velez R. Plasmodium falciparum in asymptomatic immigrants from sub-Saharan Africa, Spain. Emerg. Infect. Dis. 18, 356-357 (2012).
25. Collinet-Adler S, Stauffer WM, Boulware DR, Larsen KL, Rogers TB, Williams D N. Financial implications of refugee malaria: the impact of pre-departure presumptive treatment with anti-malarial drugs. Am. J. Trop. Med. Hyg. 77, 458-463 (2007).
26. Chih DT, Heath CH, Murray RJ. Outpatient treatment of malaria in recently arrived African migrants. Med. J. Aust. 185, 598-601 (2006).
27. Sheikh M, Pal A, Wang S et al. The epidemiology of health conditions of newly arrived refugee children: a review of patients attending a specialist health clinic in Sydney. J. Paediatr. Child Health 45, 509-513 (2009).
28. Danis K, Baka A, Lenglet A et al. Autochthonous Plasmodium vivax malaria in Greece, 2011. Euro Surveill. 16, 19993 (2011).
29. Santa-Olalla Peralta P, Vazquez-Torres MC, Latorre-Fandos E et al. First autochthonous malaria case due to Plasmodium vivax since eradication, Spain, October 2010. Euro Surveill. 15, 19684 (2010).
30. Hagmann S, Khanna K, Niazi M, Purswani M, Robins E B. Congenital malaria, an important differential diagnosis to consider when evaluating febrile infants of immigrant mothers. Pediatr. Emerg. Care 23, 326-329 (2007).
31. Kitchen AD, Barbara JA, Hewitt PE. Documented cases of post-transfusion malaria occurring in England: a review in relation to current and proposed donor-selection guidelines. Vox Sang. 89, 77-80 (2005).
32. Scuracchio P, Vieira SD, Dourado DA et al. Transfusion-transmitted malaria: case report of asymptomatic donor harboring Plasmodium malariae. Rev. Inst. Med. Trop. San Paulo 53, 55-59 (2011).
33. Hung CC, Chang SC, Chen YC, Yen TS, Hsieh W C. Plasmodium vivax infection in a renal transplant recipient: report of a case. J. Formos. Med. Assoc. 93, 888-889 (1994).
34. Chiche L, Lesage A, Duhamel C et al. Post transplant malaria: first case of transmission of Plasmodium falciparum from a white multiorgan donor to four recipients. Transplantation 75, 166-168 (2003).
35. Monge-Maillo B, Lopez-Velez R. Is screening for malaria necessary among asymptomatic refugees and immigrants coming from endemic countries? Expert Rev. Anti Infect. Ther. 9, 521-524 (2011).
36. Van Herck K, Van Damme P, Castelli F et al. Knowledge, attitudes and practices in travel-related infectious diseases: the European airport survey. J. Travel Med. 11, 3-8 (2004).
37. Maltha J, Gillet P, Jacobs J. Malaria rapid diagnostic tests in travel medicine. Clin. Microbiol. Infect. 19, 408-415 (2013).
38. WHO Malaria Rapid Diagnostic Test Performance. www.who.int/tdr/publications/documents
39. Foster D, Cox-Singh J, Mohamad DSA et al. Evaluation of three rapid dignostic tests for the detection of human infections with Plasmodium knowlesi. Malaria J. 13, 60 (2014).
40. Roukens AH, Berg J, Barbey A, Visser LG. Performance of self-diagnosis and standby treatment of malaria in international oilfield service employees in the field. Malar. J. 7, 128 (2008).
41. Babiker HA, Schneider P. Application of molecular methods for monitoring transmission stages of malaria parasites. Biomed. Mater. 3, 034007 (2008).
42. Stauffer WM, Newberry AM, Cartwright CP et al. Evaluation of malaria screening in newly arrived refugees to the United States by microscopy and rapid antigen capture enzyme assay. Pediatr. Infect. Dis. J. 25, 948-950 (2006).
43. Ndao MF, Bandyayera E, Kokoskin E et al. Comparison of blood smear, antigen detection, and nested-PCR methods for screening refugees from regions where malaria is endemic after a malaria outbreak in Quebec, Canada. J. Clin. Microbiol. 42, 2694-2700 (2004).
44. Treatment Guidelines from The Medical Letter. Drugs for parasitic infections. http://gorgas.dom.uab.edu
45. Askling HH, Bruneel F, Burchard G et al. European Society for Clinical Microbiology and Infectious Diseases Study Group on Clinical Parasitology: management of imported malaria in Europe. Malar. J. 11, 328 (2012).
46. World Health Organization. Guidelines for the Treatment of Malaria (2nd Edition). March 2010. http://whqlibdoc.who.int/publications
47. Llanos-Cuentas A, Lacerda MV, Rueangweerayut R et al. Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study. Lancet 383, 1049-1058 (2014).
48. Fatih FA, Staines HM, Siner A et al. Susceptibility of human Plasmodium knowlesi infections to anti-malarials. Malar. J. 12, 425 (2013).
49. Yansouni CP, Bottieau E, Lutumba P et al. Rapid diagnostic tests for neurological infections in central Africa. Lancet Infect. Dis. 13, 546-558 (2013).
50. Urech K, Neumayr A, Blum J. Sleeping sickness in travelers: do they really sleep? PLoS Negl. Trop. Dis. 5, e1358 (2011).
51. Babokhov P, Sanyaolu AO, Oyibo WA, Fagbenro-Beyioku AF, Iriemenam NC. A current analysis of chemotherapy strategies for the treatment of human African trypanosomiasis. Pathog. Glob. Health 107, 242-252 (2013).
52. Priotto G, Kasparian S, Mutombo W et al. Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial. Lancet. 374, 56-64 (2009).
53. Barrett M P. Potential new drugs for human African trypanosomiasis: some progress at last. Curr. Opin. Infect. Dis. 23, 603-608 (2010).
54. Hira PR, Husein SF. Some transfusion-induced parasitic infections in Zambia. J. Hyg. Epidemiol. Microbiol. Immunol. 23, 436-444 (1979).
55. Rocha G, Martins A, Gama G, Brandao F, Atouguia J. Possible cases of sexual and congenital transmission of sleeping sickness. Lancet 363, 247 (2004).
56. Basile L, Jansa JM, Carlier Y et al. Working Group on Chagas disease: Chagas disease in European countries: the challenge of a surveillance system. Euro Surveill. 16, 19968 (2011).
57. Norman FF, Lopez-Velez R. Chagas disease and breast-feeding. Emerg. Infect. Dis. 19, 1561-1566 (2013).
58. Perez-Molina JA, Rodriguez-Guardado A, Soriano A et al. Chagas Study Group of the SEMTSI (Sociedad Espanola de Medicina Tropical Y Salud Internacional): guidelines on the treatment of chronic coinfection by Trypanosoma cruzi and HIV outside endemic areas. HIV Clin. Trials 12, 287-298 (2011).
59. Flores-Chavez M, De Fuentes I, Gaárate T, Canñvate C. Diagnóstico de laboratorio de la enfermedad de Chagas importada. Enferm. Infecc. Microbiol. Clin. 25, 29-37 (2007).
60. Riera C, Verges M, Iniesta L et al. Identification of a Western blot pattern for the specific diagnosis of Trypanosoma cruzi infection in human sera. Am. J. Trop. Med. Hyg. 86, 412-416 (2012).
61. Perez-Ayala A, Perez-Molina JA, Norman F et al. Chagas disease in Latin American migrants: a Spanish challenge. Clin. Microbiol. Infect. 17, 1108-1113 (2011).
62. Coura JR, Borges-Pereira J. Chronic phase of Chagas disease: why should it be treated? A comprehensive review. Mem. Inst. Oswaldo Cruz 106, 641-645 (2011).
63. Perez-Molina JA, Perez-Ayala A, Moreno S, Fernandez-Gonzalez MC, Zamora J, Lopez-Velez R. Use of benznidazole to treat chronic Chagas' disease: a systematic review with a meta-analysis. J. Antimicrob. Chemother. 64, 1139-1147 (2009).
64. Murcia L, Carrilero B, Munoz-Davila MJ et al. Risk factors and primary prevention of congenital Chagas disease in a non-endemic country. Clin. Infect. Dis. 56, 496-502 (2013).
65. Perez-Molina JA, Sojo-Dorado J, Norman F et al. Nifurtimox therapy for Chagas disease does not cause hypersensitivity reactions in patients with such previous adverse reactions during benznidazole treatment. Acta Trop. 127, 101-104 (2013).
66. Chippaux JP, Salas-Clavijo AN, Postigo JR, Schneider D, Santalla JA, Brutus L. Evaluation of compliance to congenital Chagas disease treatment: results of a randomised trial in Bolivia. Trans. R. Soc. Trop. Med. Hyg. 107, 1-7 (2013).
67. Molina I, Gómez i Prat J, Salvador F et al. Randomized trial of posaconazole and benznidazole for chronic Chagas' disease. N. Engl. J. Med. 370, 1899-1908 (2014).
68. Desjeux P. Leishmaniasis: current situation and new perspectives. Comp. Immunol. Microbiol. Infect. Dis. 27, 305-318 (2004).
69. Pavli A, Maltezou HC. Leishmaniasis: an emerging infection in travelers. Int. J. Infect. Dis. 14, e1032-e1039 (2010).
70. Perez-Ayala A, Norman F, Perez-Molina JA, Herrero JM, Monge B, Lopez-Velez R. Imported leishmaniasis: a heterogeneous group of diseases. J. Travel Med. 16, 395-401 (2009).
71. Leder K, Torresi J, Libman MD et al. GeoSentinel Surveillance Network: GeoSentinel surveillance of illness in returned travelers, 2007-2011. Ann. Intern. Med. 158, 456-468 (2013).
72. Herremans T, Pinelli E, Casparie M, Nozari N, Roelfsema J, Kortbeek L. Increase of imported Leishmaniasis in the Netherlands: a twelve year overview (1996-2007). Int. Health. 2, 42-46 (2010).
73. Lawn SD, Whetham J, Chiodini PL et al. New world mucosal and cutaneous leishmaniasis: an emerging health problem among British travellers. QJM 97, 781-788 (2004).
74. Ehehalt U, Schunk M, Jensenius M et al. Leishmaniasis acquired by travellers to endemic regions in Europe: a EuroTravNet multi-centre study. Travel Med. Infect. Dis. 12, 167-172 (2014).
75. van Griensven J, Carrillo E, Lopez-Velez R, Lynen L, Moreno J. Leishmaniasis in immunosuppressed individuals. Clin. Microbiol. Infect. 20, 286-299 (2014).
76. Monge-Maillo B, Lopez-Velez R. Therapeutic options for visceral leishmaniasis. Drugs 73, 1863-1888 (2013).
77. Monge-Maillo B, Lopez-Velez R. Therapeutic options for old world cutaneous leishmaniasis and new world cutaneous and mucocutaneous leishmaniasis. Drugs 73, 1889-1920 (2013).
78. Blum J, Buffet P, Visser L et al. LeishMan recommendations for treatment of cutaneous and mucosal leishmaniasis in travelers, 2014. J. Travel Med. 21, 116-129 (2014).
79. Sosa N, Capitan Z, Nieto J et al. Randomized, double-blinded, phase 2 trial of WR 279,396 (paromomycin and gentamicin) for cutaneous leishmaniasis in Panama. Am. J. Trop. Med. Hyg. 89, 557-563 (2013).
80. Soto J, Rojas E, Guzman M et al. Intralesional antimony for single lesions of Bolivian cutaneous leishmaniasis. Clin. Infect. Dis. 56, 1255-1260 (2013).
81. Monge-Maillo B, Perez-Molina JA, Norman FF, Lopez-Velez R. Concerns about topical treatment for new world cutaneous leishmanisis. Clin. Infect. Dis. 57, 1502-1503 (2013).
82. Barratt JL, Harkness J, Marriott D, Ellis JT, Stark D. Importance of non-enteric protozoan infections in immunocompromised people. Clin. Microbiol. Rev. 23, 795-836 (2010).
83. Pappas G, Roussos N, Falagas M E. Toxoplasmosis snapshots: global status of Toxoplasma gondii seroprevalence and implications for pregnancy and congenital toxoplasmosis. Int. J. Parasitol. 39, 1385-1394 (2009).
84. Ramos JM, Milla A, Rodriguez JC, Padilla S, Masia M, Gutierrez F. Seroprevalence of Toxoplasma gondii infection among immigrant and native pregnant women in eastern Spain. Parasitol. Res. 109, 1447-1452 (2011).
85. Bottieau E, Clerinx J, Van den Enden E et al. Infectious mononucleosis-like syndromes in febrile travelers returning from the tropics. J. Travel Med. 13, 191-197 (2006).
86. Shwab EK, Zhu XQ, Majumdar D et al. Geographical patterns of Toxoplasma gondii genetic diversity revealed by multilocus PCR-RFLP genotyping. Parasitology 141, 453-461 (2014).
87. Wujcicka W, Wilczynski J, Nowakowska D. Do the placental barrier, parasite genotype and Toll-like receptor polymorphisms contribute to the course of primary infection with various Toxoplasma gondii genotypes in pregnant women? Eur. J. Clin. Microbiol. Infect. Dis. 33, 703-709 (2014).
88. Khan A, Jordan C, Muccioli C et al. Genetic divergence of Toxoplasma gondii strains associated with ocular toxoplasmosis, Brazil. Emerg. Infect. Dis. 12, 942-949 (2006).
89. Warne B, Weld LH, Cramer JP et al. EuroTravNet Network: travel-related Infection in European travelers, EuroTravNet 2011. J. Travel Med. doi: 10.1111/jtm.12120 (2014) (Epub ahead of print).
90. Lebbad M, Petersson I, Karlsson L et al. Multilocus genotyping of human Giardia isolates suggests limited zoonotic transmission and association between assemblage B and flatulence in children. PLoS Negl. Trop. Dis. 5, e1262 (2011).
91. Ballweber LR, Xiao L, Bowman DD, Kahn G, Cama VA. Giardiasis in dogs and cats: update on epidemiology and public health significance. Trends Parasitol. 26, 180-189 (2010).
92. Nguyen TK, Kherouf H, Blanc-Pattin V et al. Evaluation of an immunochromatographic assay: Giardia-Strip(R) (Coris BioConcept) for detection of Giardia intestinalis in human fecal specimens. Eur. J. Clin. Microbiol. Infect. Dis. 31, 623-625 (2012).
93. Wright S G. Protozoan infections of the gastrointestinal tract. Infect. Dis. Clin. North Am. 26, 323-339 (2012).
94. Paz-Maldonado MT, Arguello-Garcia R, Cruz-Soto M, Mendoza-Hernandez G, Ortega-Pierres G. Proteomic and transcriptional analyses of genes differentially expressed in Giardia duodenalis clones resistant to albendazole. Infect. Genet. Evol. 15, 10-17 (2013).
95. Carlos E, Granados, Ludovic Reveiz, Uribe Luis G and Criollo Claudia P. Drugs for treating giardiasis. Cochrane Database Syst. Rev. 12, CD007787 (2012).
96. Lopez-Velez R, Batlle C, Jimenez C, Navarro M, Norman F, Perez-Molina J. Short course combination therapy for giardiasis after nitroimidazole failure. Am. J. Trop. Med. Hyg. 83. 171-173 (2010).
97. Nagata N, Shimbo T, Akiyama J et al. Risk factors for intestinal invasive amebiasis in Japan, 2003-2009. Emerg. Infect. Dis. 18, 717-724 (2012).
98. Herbinger KH, Fleischmann E, Weber C, Perona P, Loscher T, Bretzel G. Epidemiological, clinical, and diagnostic data on intestinal infections with Entamoeba histolytica and Entamoeba dispar among returning travelers. Infection 39, 527-535 (2011).
99. van Hal SJ, Stark DJ, Fotedar R, Marriott D, Ellis JT, Harkness J L. Amoebiasis: current status in Australia. Med. J. Aust. 186, 412-416 (2007).
100. Tasawar Z, Kausar S, Lashari M H. Prevalence of Entamoeba histolytica in humans. Pak. J. Pharm. Sci. 23, 344-348 (2010).
101. Morf L, Singh U. Entamoeba histolytica: a snapshot of current research and methods for genetic analysis. Curr. Opin. Microbiol. 15, 469-475 (2012).
102. Cordel H, Prendki V, Madec Y et al. ALA Study Group: imported amoebic liver abscess in France. PLoS Negl. Trop. Dis. 7, e2333 (2013).
103. Gutierrez-Cisneros MJ, Cogollos R et al. Application of real-time PCR for the differentiation of Entamoeba histolytica and E. dispar in cyst-positive faecal samples from 130. immigrants living in Spain. Ann. Trop. Med. Parasitol. 104, 145-149 (2010).
104. Gonzales ML, Dans LF, Martinez EG. Antiamoebic drugs for treating amoebic colitis. Cochrane Database Syst. Rev. 15(2), CD006085 (2009).
105. Shirley DA, Moonah SN, Kotloff K L. Burden of disease from cryptosporidiosis. Curr. Opin. Infect. Dis. 25, 555-563 (2012).
106. Baldursson S, Karanis P. Waterborne transmission of protozoan parasites: review of worldwide outbreaks: an update 2004-2010. Water Res. 45, 6603-6614 (2011).
107. Soonawala D, van Lieshout L, den Boer MA Claas EC, Verweij JJ, Godkewitsch A, Ratering M, Visser L G et al. Post-travel screening of asymptomatic long-term travelers to the tropics for intestinal parasites using molecular diagnostics. Am. J. Trop. Med. Hyg. 90, 835-839 (2014).
108. Fournet N, Deege MP, Urbanus AT et al. Simultaneous increase of Cryptosporidium infections in the Netherlands, the United Kingdom and Germany in late summer season, 2012. Euro Surveill. 18, 20348 (2013).
109. Ortega YR, Sanchez R. Update on Cyclospora cayetanensis, a food-borne and waterborne parasite. Clin. Microbiol. Rev. 23, 218-234 (2010).
110. Clarke SC, McIntyre M. The incidence of Cyclospora cayetanensis in stool samples submitted to a district general hospital. Epidemiol. Infect. 117, 189-193 (1996).
111. Zhou Y, Lv B, Wang Q et al. Prevalence and molecular characterization of Cyclospora cayetanensis, Henan, China. Emerg. Infect. Dis. 17, 1887-1890 (2011).
112. Centers for Diseases Control and Prevention (CDC). Parasites: cyclosporiasis. www.cdc.gov/parasites/cyclosporiasis.
113. Perez-Ayala A, Monge-Maillo B, Diaz-Menendez M, Norman F, Perez-Molina JA, Lopez-Velez R. Self-limited travelers' diarrhea by Isospora belli in a patient with dengue infection. J. Travel Med. 18, 212-213 (2011)
114. Taniuchi M, Verweij JJ, Sethabutr O et al. Multiplex polymerase chain reaction method to detect cyclospora, cystoisospora, and microsporidia in stool samples. Diagn. Microbiol. Infect. Dis. 71, 386-390 (2011).
115. Lopez-Velez R, Turrientes MC, Garron C et al. Microsporidiosis in travelers with diarrhea from the tropics. J. Travel Med. 6, 223-227 (1999).
116. Wichro E, Hoelzl D, Krause R, Bertha G, Reinthaler F, Wenisch C. Microsporidiosis in travel-associated chronic diarrhea in immune-competent patients. Am. J. Trop. Med. Hyg. 73, 285-287 (2005).
117. Wong KT, Pathmanathan R. High prevalence of human skeletal muscle sarcocystosis in south-east Asia. Trans. R. Soc. Trop. Med. Hyg. 86, 631-632 (1992).
118. Centers for Disease Control and Prevention (CDC). Notes from the field: acute muscular sarcocystosis among returning travelers-Tioman Island, Malaysia, 2011. MMWR Morb. Mortal. Wkly Rep. 61, 37-38 (2012).
119. Esposito DH, Freedman DO, Neumayr A, Parola P. Ongoing outbreak of an acute muscular sarcocystis-like illness among travellers returning from Tioman Island, Malaysia, 2011-2012. Euro Surveill. 17, 20310 (2012).
120. Centers for Disease Control and Prevention (CDC). Travelers' health: sarcocystosis in Malaysia. wwwnc.cdc.gov/travel/notices/watch